We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





World's First Patient-Controlled Nasopharyngeal Swab Robot for COVID-19 Testing Reduces Risk of Exposure to SARS-CoV-2

By LabMedica International staff writers
Posted on 23 Sep 2020
A new robot for automated COVID-19 swab test could provide a solution to protect and reduce the risk of exposure faced by healthcare workers to the SARS-CoV-2 virus.

Biobot Surgical Pte Ltd (Singapore) has developed the SwabBot, a robot for automated swab, to address the challenges of COVID-19 swab test. More...
In addition to protecting and reducing the healthcare workers’ risk of exposure to the novel coronavirus, it also standardizes the consistency of swabs taken while providing greater throughput of swab tests.

The SwabBot is a robot which allows individuals to self-administer the swabbing process. By pushing the chin and face forward against activation button, it activates the robot which gently inserts a swab stick through the nose to the back of the nasal cavity. The duration of the swab takes only 20 seconds. To ensure the safety of the individual, the robot has a built-in feature which retracts the swab stick if there is resistance in moving deeper into the nasal cavity.

“When we developed the SwabBot, we envisaged a self swabbing device that could be deployed and used, similar to how self check-out systems are now prevalent in the supermarkets. This should be especially effective for rostered routine testing and reduce manpower involved in swabbing operations,” said Mr. Sim Kok Hwee, CEO of Biobot Surgical.

Related Links:
Biobot Surgical Pte Ltd


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Electrolyte Analyzer
BKE-B
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.